Regulation - Research, Gastro-intestinals

Filter

Popular Filters

AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA

22-05-2013

Anglo-Swedish drug major AstraZeneca (LSE: AZN) yesterday (May 21) presented the results of two pivotal…

Anti-viralsAstraZenecaBiotechnologyEuropeGastro-intestinalsGilead SciencesnaloxegolNektar TherapeuticsPharmaceuticalRegulationResearchsofosbuvir

News briefs: Lexicon's IBS drug; Sanofi Pasteur launch in Thailand; Tranzyme drops TZP-102

17-12-2012

US drug developer Lexicon Pharmaceuticals (Nasdaq: LXRX) saw its shares leap 9.1% to $2.04 in premarket…

DiabetesGastro-intestinalsLexicon PharmaceuticalsLX1033Markets & MarketingPharmaceuticalRegulationResearchSanofiSanofi PasteurTranzymeTZP-102Vaccines

Research news: dolutegravir; TD-1211; and synaptic modulators

11-07-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Japanese drugmaker Shionogi (TYO: 4507) have reported…

Anti-viralsdolutegravirGalenea CorpGastro-intestinalsGlaxoSmithKlineLicensingNeurologicalPharmaceuticalRegulationResearchShionogiTD-1211TheravanceZonegran

US FDA accepts Ironwood and Forest’s NDA for IBS drug linaclotide; new data from Almirall

24-10-2011

US drugmakers Ironwood Pharmaceuticals (Nasdaq: IRWD) and Forest Laboratories (NYSE: FRX) said yesterday…

AlmirallForest LaboratoriesGastro-intestinalsIronwood PharmaceuticalslinaclotideNorth AmericaPharmaceuticalRegulationResearch

Back to top